The specialist cancer drug discovery and development business has provided a trading update for the year ending 20 June 2019. In many ways 2019 has been an astonishing validation for Sareum’s strategy of designing best in class targeted therapeutics focussing on emerging but clinically justified targets. The first Sareum candidate to enter human trials, the oral selective Chk1 inhibitor SRA737, currently under the stewardship of Sierra Oncology (SRRA) demonstrated notable anti-cancer ac
20 Aug 2019
TYK2/JAK1 programs attracting interest from international pharma. Trading ahead of expectations.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
TYK2/JAK1 programs attracting interest from international pharma. Trading ahead of expectations.
Sareum Holdings plc (SAR:LON) | 30.5 -0.9 (-9.0%) | Mkt Cap: 31.0m
- Published:
20 Aug 2019 -
Author:
Derren Nathan -
Pages:
7
The specialist cancer drug discovery and development business has provided a trading update for the year ending 20 June 2019. In many ways 2019 has been an astonishing validation for Sareum’s strategy of designing best in class targeted therapeutics focussing on emerging but clinically justified targets. The first Sareum candidate to enter human trials, the oral selective Chk1 inhibitor SRA737, currently under the stewardship of Sierra Oncology (SRRA) demonstrated notable anti-cancer ac